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Background: The use of thiazolidinediones (TZDs) has been associated with increased
fracture risks. Our aim was to estimate the risk of fracture with TZDs in three different
healthcare registries, using exactly the same study design, and to perform an individual
patient data meta-analysis of these three studies.
Methods: Population-based cohort studies were performed utilizing the British General
Practice Research Database (GPRD), the Dutch PHARMO Record Linkage System (RLS),
and the Danish National Health Registers. In all three databases, the exposed cohort
consisted of all patients (aged 18+) with at least one prescription of antidiabetic (AD)
medication. Cox proportional hazards models were used to estimate hazard ratios (HRs) of
fracture. The total period of follow-up for each patient was divided into periods of current
exposure and past exposure, with patients moving between current and past use.
Results: In all three registries, the risk of fracture was increased for women who were
exposed to TZDs: HR 1.48 (1.37–1.60) in GPRD, HR 1.35 (1.15–1.58) in PHARMO, and HR
1.22 (1.03–1.44) in Denmark. Combining the data in an individual patient data meta-analysis
resulted, for women, in a 1.4-fold increased risk of any fracture for currentTZD users versus
other AD drug users [adj. HR 1.44 (1.35–1.53)]. For men, there was no increased fracture risk
[adj. HR 1.05 (0.96–1.14)]. Risks were increased for fractures of the radius/ulna, humerus,
tibia/fibula, ankle, and foot, but not for hip/femur or vertebral fractures. Current TZD users
with more than 25 TZD prescriptions ever before had a 1.6-fold increased risk of fracture
compared with other AD drug users [HR 1.59 (1.46–1.74)].
Conclusion: In this study, we consistently found a 1.2- to 1.5-fold increased risk of fractures
for women using TZDs, but not for men, across three different healthcare registries. TZD
users had an increased risk for fractures of the extremities, and risks further increased for
prolonged users of TZDs.
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INTRODUCTION
Thiazolidinediones (TZDs) have been demonstrated to improve
insulin resistance when applied to patients with Type 2 Diabetes
Mellitus (T2DM). TZDs exert their insulin-sensitizing actions
either directly, by promoting fatty acid uptake and storage in adi-
pose tissue, or indirectly, by means of altered adipokine release
(Yki-Jarvinen, 2004). Recently, an association of rosiglitazone with
risk of cardiovascular outcomes (Schernthaner and Chilton, 2010)
has led to withdrawal of the drug in Europe and restricted access in
the United States, but pioglitazone is still used in the management
of T2DM. Beneficial effects of pioglitazone use have been reported
in patients with a recent acute myocardial infarction (Erdmann
et al., 2007) as well as in patients with non-alcoholic steatohepatitis
(Sanyal et al., 2010).
The increased adipogenesis caused by TZDs is to the detriment
of the genesis of bone-forming osteoblasts (Benvenuti et al., 2007;
Grey, 2008). Several studies have found that TZD use leads to
a decreased bone mineral density (BMD) and an elevated risk of
fracture (Betteridge, 2011). Women who were exposed to TZDs for
3–4 months had significantly reduced BMD at the lumbar spine
and hip in two randomized controlled trials (Glintborg et al., 2008;
Grey et al., 2011). A meta-analysis from 10 randomized controlled
trials (Loke et al., 2009) showed that the use of rosiglitazone and
pioglitazone was associated with a significantly increased risk of
fractures [Odds Ratio 1.45 (95% CI 1.18–1.79)].
Observational studies have provided some contrasting results
regarding sex difference and the type of fractures (Betteridge,
2011). This may be due to differences in study designs, study
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populations, the recording/under-recording of certain fracture
types, the use of co-medication, the type of patients that are
prescribed TZDs, and other potential causes of bias that exist in
observational research.
Therefore, the first aim of this study was to estimate the risk of
fracture with TZDs in three different healthcare registries, using
exactly the same study design. This allowed us to compare in a
consistent manner the patient characteristics of TZD users, the
use of co-medication, the occurrence of fractures, and the risks of
fracture for TZD users between these registries. The second aim
was to perform an individual patient data meta-analysis of these
three studies on the risk of fracture in TZD users, stratified by
fracture type, sex, and duration of use.
MATERIALS AND METHODS
DATA SOURCES
This study used data from the British General Practice Research
Database (GPRD) which is part of the Clinical Practice Research
Datalink, the Dutch PHARMO Record Linkage System (RLS), and
the Danish National Health Registers.
The GPRD comprises computerized medical records for over
10 million patients under the care of general practitioners (GPs) in
the United Kingdom (UK). The data recorded in the GPRD since
1987 include demographic information, prescription details, clin-
ical events, preventive care provided, specialist referrals, hospital
admissions, and their major outcomes. In the UK, the GP typically
manages the prescribing for chronic diseases such as diabetes. A
recent review of all validation studies found that medical data in
the GPRD were generally of high quality (Herrett et al., 2010).
PHARMO RLS links the use of prescription drugs (phar-
macy database, including dispensed drug, dispensing date,
amount dispensed, and written dosage instructions) and diagnos-
tic/therapeutic data from hospitals to the same patient. Currently,
data are collected from a population of about three million resi-
dents in the Netherlands and are representative of the total Dutch
population. A previous study of PHARMO RLS data has shown
a high level of data validity with respect to the reporting of hip
fractures (>89% of fractures were confirmed; Herings et al., 1996).
In Denmark, separate registers of computerized medical
records on all contacts to hospitals and on the use of drugs can be
linked for the entire population. The Ministry of the Interior keeps
records of all inhabitants, including their migrations and dates of
birth and death. Information on hospital admissions comes from
the National Hospital Discharge Register (Andersen et al., 1999),
which covers all inpatient contacts from 1977 onward and from
1995 also all outpatient visits to hospitals, outpatient clinics, and
emergency rooms. The register has an almost 100% capture of
contacts and the validity of registrations is high (Mosbech et al.,
1995). The Danish Medicines Agency keeps a nationwide register
of all prescription drugs sold at pharmacies throughout the coun-
try from 1996 onward, the National Pharmacological Database
(www.dkma.dk). All prescriptions are registered with ATC code,
dosage, and date.
STUDY POPULATIONS
In all three registries, the exposed cohort consisted of all patients
(aged 18+) with at least one prescription of antidiabetic (AD)
medication during valid data collection (GPRD: between 1987
and 2010, PHARMO: 1998 and 2008, Denmark: 1996 and 2007).
The date of the first AD prescription within this period defined
the index date. Patients with only a recorded prescription of
insulin at their index date were excluded from the cohort.
Therefore, all patients had a record of a non-insulin antidia-
betic drug (NIAD) prescription on their index date. NIAD drug
users were matched by year of birth and sex to control persons,
who did not have an AD (NIAD or insulin) prescription any
time during follow-up. In GPRD, one control was matched to
each exposed patient, in PHARMO four controls and in Den-
mark three controls per patient. Controls were assigned the same
index date as their matched NIAD drug user. All participants
were followed from the index date to the end of data collec-
tion, the patient’s transfer out of the registry, emigration, or the
patient’s death, whichever came first. The study populations from
PHARMO and Denmark have been described before (Bazelier
et al., 2012a,b).
EXPOSURE
The total period of follow-up for each patient was divided into
periods of current exposure and past exposure, with patients
moving between current and past use. In GPRD, each period
of current exposure started with an AD prescription and ended
3 months later, or on the date that a new AD drug was pre-
scribed within this period. In PHARMO and the Danish registries,
each period of current exposure started with an AD prescription
and ended 3 months after the expected duration of AD therapy,
or on the date that a new AD drug was prescribed within this
period. In PHARMO, the expected duration of NIAD therapy
was based on the total quantity and the prescribed daily dose.
In case of missing data, the median expected duration of treat-
ment (based on data of other NIAD prescriptions) was used. For
insulin treatment, the median time between two insulin injections
(based on all insulin prescriptions) was taken as the expected
duration of use. In Denmark, the expected duration of NIAD
therapy was defined as the median time between two NIAD
prescriptions, based on all NIAD prescriptions. For insulin treat-
ment, the median time between two insulin injections (based on
all insulin prescriptions) was taken as the expected duration of
use.
At the start of each interval, each patient was classified as a
current user of AD medication if they had an AD prescription on
that start date or in the 3 months before. The current user sta-
tus was determined for five different groups of AD medication:
biguanides, sulfonylureas, TZDs, insulin, or other ADs (includ-
ing Dipeptidyl Peptidase 4 inhibitors, glinides, Glucagon-Like
Peptide-1 analogs, and alpha glucosidase inhibitors). For control
persons, the total period of follow-up was divided into periods of
6 months.
STUDY OUTCOMES
Patients were followed up for the occurrence of a first fracture.
The types of fracture were classified according to the Inter-
national Classification of Diseases (ICD-10) categories. These
included S02, S12, S22, S32, S42, S52, S62, S72, S82, S92, T02,
T08, T10, and T12. An osteoporotic fracture was defined as a
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Table 1 | Baseline characteristics.
GPRD PHARMO Danish registries
Diabetic patients Controls Diabetic patients Controls Diabetic patients Controls
n=196,024 n=196,024 n=123,452 n=451,388 n=180,049 n=490,147
Mean duration of follow-up after
index date, yrs (range)
4.7 (0.0–21.4) 4.6 (0.0–21.5) 4.5 (0.0–11.0) 4.0 (0.0–11.0) 5.3 (0.0–12.0) 6.2 (0.0–12.0)
Sex female 45.1% 45.1% 52.5% 52.9% 47.0% 47.4%
Mean age at index date 65.0 65.0 64.0 64.0 62.6 62.5
BMI
<20 1.5% 4.5%
20–25 14.7% 28.9%
25–30 34.0% 32.3%
>30 44.5% 15.9%
Unknown 5.4% 18.4%
SMOKING
Never 41.1% 41.8%
Current 17.8% 18.8%
Ex 32.3% 22.1%
Unknown 8.8% 17.4%
COMORBIDITY 1YEAR BEFORE (a)
Fracture 1.2% 1.2% 0.5% 0.6% 2.4% 2.3%
Congestive heart failure 1.6% 0.7% 0.1% 0.1% 0.6% 0.1%
Rheumatoid arthritis 0.3% 0.3% 0.1% 0.1% 0.3% 0.2%
Cerebrovascular disease 2.2% 1.1% 0.9% 0.5% 2.6% 0.9%
Inflammatory bowel disease 0.2% 0.1% 0.2% 0.1% 0.4% 0.2%
Epilepsy 0.5% 0.5% 0.1% 0.1% 0.3% 0.2%
Diabetic retinopathy 2.8% 0.0% 0.0% 0.0% 0.9% 0.0%
DRUG USE 1YEAR BEFORE (a)
Statins 36.5% 12.4% 26.1% 13.9% 16.9% 6.3%
Antidepressants 15.7% 10.4% 10.0% 7.7% 12.2% 8.3%
Antipsychotics 2.9% 1.5% 3.1% 2.2% 5.7% 2.9%
Anxiolytics/hypnotics 10.4% 8.4% 23.6% 20.8% 21.1% 17.4%
Anticonvulsants 3.0% 2.2% 2.7% 2.3% 2.6% 1.9%
Opioids 4.9% 2.9% 7.6% 5.6% 13.5% 8.7%
Oral glucocorticoids 6.8% 4.4% 10.7% 6.7% 8.3% 5.0%
Bisphosphonates 2.0% 2.5% 3.0% 3.3% 1.0% 1.4%
Estrogen 1.2% 1.9% 2.5% 3.0% 4.5% 5.5%
Calcium 0.5% 0.5% 2.9% 3.3% 0.9% 0.9%
Vitamin D 2.7% 2.8% 0.8% 0.8% 0.1% 0.1%
Thiazide diuretics 20.9% 13.2% 8.4% 4.4% 19.3% 10.1%
(a) Within people with more than 1 year of data collection.
fracture of the radius/ulna, vertebrae, femur, hip, humerus, pelvis,
or ribs.
STATISTICAL ANALYSIS
Incidence rates of fractures were estimated for diabetic patients
and for controls. We computed person-years of follow-up by
adding all person-time from the start date to either the date of first
fracture or to the date of censoring, if no fracture had occurred.
The incidence rate of fracture was defined as the number of frac-
tures per 1,000 person-years. To study patient characteristics of
TZD users, we randomly selected one TZD prescription for every
patient who ever used a TZD during follow-up.
We compared risks of fracture in current users of TZDs with
that in users of other AD medication, using a time-dependent Cox
proportional hazards analysis. The analyses were adjusted for age
and sex, and fracture risks were stratified by fracture type and
sex. First, this was done for every registry separately. Then, we
combined all records in an individual patient data meta-analysis
and estimated fracture risks, thereby also adjusting for the ori-
gin of the data (i.e., GPRD, PHARMO, or Denmark). In a fully
adjusted analysis we additionally adjusted for current use of other
AD medication.
To investigate the risk of fracture in prolonged users of TZDs,
we stratified fracture risks in current TZD users by number of TZD
www.frontiersin.org February 2013 | Volume 4 | Article 11 | 3
Bazelier et al. Risk of fracture with thiazolidinediones
Table 2 | Use of antidiabetic medication and incidence rate of fractures during follow-up.
GPRD PHARMO Danish registries
Diabetic patients Controls Diabetic patients Controls Diabetic patients Controls
n=196,024 n=196,024 n=123,452 n=451,388 n=180,049 n=490,147
ANTIDIABETIC DRUG USE-ANYTIME DURING FOLLOW-UP
Biguanide 83.7% – 80.8% – 68.2% –
Sulfonylureum 62.4% – 70.1% – 76.3% –
Thiazolidinedione 19.5% – 12.2% – 4.2% –
Insulin 13.1% – 21.3% – 23.6% –
Other 8.9% – 3.5% – 9.9% –
INCIDENCE RATE OF FRACTURE (a)
Any fracture 10.33 9.94 7.92 7.42 27.36 23.90
Osteoporotic fracture 5.82 5.85 6.34 5.96 17.76 15.85
Hip 1.66 1.53 3.94 3.70 6.72 5.46
Vertebral 0.48 0.52 0.39 0.36 1.45 1.20
Radius/ulna 1.46 1.77 0.48 0.59 4.63 5.45
Femur 0.28 0.25 0.27 0.24 0.67 0.49
Pelvis 0.29 0.27 0.37 0.34 0.63 0.60
Humerus 1.19 1.06 0.56 0.47 3.48 2.56
Ribs 0.56 0.53 0.32 0.27 0.92 0.75
Patella 0.11 0.10 0.09 0.07 0.32 0.28
Tibia/fibula 0.47 0.36 0.32 0.28 2.71 2.00
Ankle 0.86 0.69 0.62 0.48 2.01 1.39
Foot 0.73 0.67 0.10 0.07 1.83 1.52
(a) Number of fractures per 1,000 person-years.
Table 3 | Characteristics of currentTZD users, based on one random
prescription per patient.
GPRD PHARMO Danish registries
RandomTZD
prescriptions
RandomTZD
prescriptions
RandomTZD
prescriptions
n=38,438 n=15,118 n=7,603
Sex female 42.9% 52.1% 42.7%
Mean age at
prescription date
64.3 63.2 61.6
Mean number ofTZD
prescriptions before
14.2 6.3 7.6
Mean duration of
follow-up after index
date, yrs
4.2 3.8 5.5
CURRENT USE OF
Biguanide 77.5% 66.2% 85.2%
Sulfonylureum 53.7% 54.4% 47.2%
Insulin 5.2% 10.2% 9.4%
Other 4.7% 1.8% 6.4%
prescriptions ever before (using the multi-country dataset). Wald
tests were used to examine if there were significant differences
between differently exposed groups.
As a sensitivity analysis, we combined fracture risk esti-
mates of the three separate studies in an inverse-variance fixed
effect meta-analysis (Parmar et al., 1998). Heterogeneity statistics
were derived. All data management and statistical analyses were
conducted using SAS® 9.1/9.2 and Review Manager® 5.1 software.
RESULTS
Our study populations included 196,024 diabetic patients from
the GPRD, 123,452 patients from PHARMO, and 180,049 patients
from Denmark. Their mean age at index date (first NIAD pre-
scription) varied between 63 and 65 years. PHARMO comprised
slightly more female patients (53%) than the GPRD (45%) and the
Danish registries (47%). The mean duration of follow-up after the
index date was approximately 5 years for diabetic patients from all
three registries. The GPRD was the only database in which infor-
mation on smoking and body mass index was captured. Further
baseline characteristics are shown in Table 1.
During the study period, 19.5% of the diabetic patients from
the GPRD had been prescribed a TZD at least once (Table 2).
For PHARMO, this was 12.2% and for the Danish registries 4.2%.
Incidence rates of fracture were much higher in Denmark (27.4
fractures per 1,000 person-years for diabetic patients) than in the
GPRD and PHARMO (with incidence rates of 10.3 and 7.9, respec-
tively). The difference in incidence rates between diabetic patients
and controls was most pronounced in Denmark as well.
Table 3 shows that the GPRD comprised more prolonged users
of TZDs (with a mean amount of 14 TZD prescriptions before)
than the other two registries (6–8 TZD prescriptions before). In
the GPRD, insulin was less often prescribed together with a TZD
than in PHARMO and Denmark, but insulin use was overall lower
in the GPRD (Table 2).
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Table 4 | Risk of fracture in currentTZD users compared with other antidiabetic users, by type of fracture and sex.
GPRD PHARMO Danish registries
Fracture,
n=
Age-sex
adj HR
CI Fracture,
n=
Age-sex
adj HR
CI Fracture,
n=
Age-sex
adj HR
CI
Control (other AD drug user) 7,245 1 3,797 1 21,202 1
CURRENTTZD USER
Any fracture 1,196 1.33 1.25 1.41 235 1.22 1.07 1.39 213 1.03 0.90 1.18
Male 401 1.10 0.99 1.22 63 0.98 0.76 1.26 74 0.79 0.63 1.00
Female 795 1.48 1.37 1.60 172 1.35 1.15 1.58 139 1.22 1.03 1.44
Osteoporotic fracture 592 1.27 1.16 1.38 176 1.23 1.06 1.44 116 0.98 0.81 1.18
Male 166 0.99 0.84 1.17 45 1.03 0.76 1.39 37 0.78 0.57 1.09
Female 426 1.42 1.28 1.57 131 1.32 1.11 1.59 79 1.11 0.88 1.38
Hip 109 0.95 0.78 1.16 86 1.08 0.87 1.35 19 0.53 0.34 0.84
Vertebral 41 0.97 0.70 1.35 17 1.80 1.08 3.00 11 1.00 0.55 1.81
Radius/ulna 189 1.59 1.35 1.86 21 1.49 0.94 2.35 43 1.23 0.91 1.67
Femur 20 1.09 0.68 1.74 11 1.87 1.00 3.52 2 0.49 0.12 1.99
Pelvis 31 1.47 1.00 2.16 8 1.06 0.52 2.17 3 0.82 0.26 2.55
Humerus 161 1.53 1.28 1.81 26 1.59 1.05 2.40 28 1.08 0.75 1.58
Ribs 54 1.07 0.80 1.43 7 0.76 0.35 1.64 11 1.38 0.76 2.52
Patella fracture 12 1.26 0.68 2.35 2 0.89 0.21 3.75 3 1.12 0.36 3.52
Tibia/fibula fracture 68 1.50 1.15 1.96 15 1.69 0.98 2.92 36 1.64 1.17 2.28
Ankle fracture 128 1.65 1.35 2.00 23 1.22 0.79 1.89 25 1.46 0.98 2.18
Foot fracture 91 1.18 0.94 1.48 4 1.46 0.51 4.18 27 1.52 1.03 2.23
Table 4 shows that current TZD users had an increased risk of
fracture compared with patients who were exposed to other AD
drugs in GPRD, in PHARMO, but not in Denmark. In all three
registries, the risk of fracture was however increased for women:
hazard ratios (HR) 1.48 (1.37–1.60) in GPRD, HR 1.35 (1.15–
1.58) in PHARMO, and HR 1.22 (1.03–1.44) in Denmark. TZD
users from the GPRD had an increased risk for fractures of the
radius/ulna, pelvis, humerus, tibia/fibula, and ankle, compared
with other AD drug users. In PHARMO and Denmark, numbers
of fractures in TZD users were generally too low to conclude any-
thing on specific fracture types. One consistent finding was that
no increased risk of hip fracture was apparent for TZD users in
any of the registries.
Combining the data in an individual patient data meta-analysis
resulted in a 1.3-fold increased risk of any fracture for current TZD
users versus other AD drug users [fully adjusted (adj.) HR 1.27
(1.21–1.34), Table 5]. There was an increased risk for women [adj.
HR 1.44 (1.35–1.53)], but not for men [adj. HR 1.05 (0.96–1.14)].
Risks were increased for fractures of the radius/ulna, humerus,
tibia/fibula, ankle, and foot, but not for hip/femur or vertebral
fractures.
Table 6 presents the stratification of current TZD users by the
number of TZD prescriptions they had before. Current TZD users
with more than 25 TZD prescriptions ever before had a 1.6-fold
increased risk of fracture compared with other AD drug users
[HR 1.59 (1.46–1.74)]. When we stratified the overall fracture risk
to risk of fractures of the extremities for women who had been
prescribed a TZD more than 25 times ever before, we found a
doubled increased fracture risk. For men, the risk of fractures of
the extremities increased from HR 1.15 (0.95–1.38) in the lowest
exposure group (1–10 prescriptions) to HR 1.31 (1.05–1.64) in the
group with largest exposure (>25 prescriptions), but differences
between these groups were not statistically significant.
A sensitivity analysis showed that a traditional meta-analysis
(presented in Figure 1) provided similar results as the results from
Table 5. For any fracture, the pooled age-sex adjusted estimate of
the individual studies was HR 1.26 (1.20–1.33). Overall, there was
significant heterogeneity between the studies (p= 0.003). How-
ever, for women only the heterogeneity statistic was not significant
(p= 0.08). For men only, the heterogeneity statistic was significant
(p= 0.04).
DISCUSSION
In this study, we consistently found a 1.2- to 1.5-fold increased risk
of fractures for women using TZDs, but not for men, across three
different healthcare registries.
Our findings are comparable to clinical trial results. A meta-
analysis capturing 10 randomized controlled trials reported that
patients who were using TZDs experienced a 1.5-fold increased
risk of fracture compared with patients using other AD drugs
[OR 1.45 (1.18–1.79)]. Another recent trial that was not incor-
porated in this meta-analysis showed a similar result [RR 1.57
(1.26–1.97); Home et al., 2009]. Both the meta-analysis and the
more recent trial found a significantly increased risk of fractures
among women but not among men, which is in line with our find-
ings. Another similarity is the finding of an excess risk of distal
fracture events.
Observational studies have also evaluated the association
between TZD use and fracture risk, providing some contrasting
results (Betteridge, 2011). Meier et al. (2008) performed a nested
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Table 5 | Multi-country: risk of fracture in currentTZD users compared with other antidiabetic users, by type of fracture and sex.
Multi-country
Fracture, n= Age-sex
adj HR
CI Fully adj
HR (a)
CI
Control (other AD drug user) 32,244 1 1
CURRENTTZD USER
Any fracture 1,644 1.25 1.18 1.31 1.27 1.21 1.34
Male 538 1.01 0.92 1.10 1.05 0.96 1.14
Female 1,106 1.42 1.33 1.51 1.44 1.35 1.53
Osteoporotic fracture 884 1.20 1.12 1.29 1.23 1.14 1.32
Male 248 0.95 0.83 1.08 0.99 0.87 1.13
Female 636 1.35 1.25 1.47 1.37 1.26 1.49
Hip 214 0.91 0.79 1.05 0.93 0.81 1.06
Vertebral 69 1.08 0.84 1.39 1.12 0.87 1.44
Radius/ulna 253 1.47 1.29 1.68 1.50 1.31 1.71
Femur 33 1.11 0.78 1.59 1.15 0.80 1.65
Pelvis 42 1.30 0.94 1.79 1.32 0.96 1.82
Humerus 215 1.48 1.28 1.71 1.53 1.32 1.77
Ribs 72 1.06 0.83 1.35 1.11 0.87 1.43
Patella fracture 17 1.09 0.65 1.80 1.13 0.68 1.87
Tibia/fibula fracture 119 1.56 1.28 1.89 1.60 1.32 1.95
Ankle fracture 176 1.53 1.30 1.80 1.57 1.34 1.85
Foot fracture 122 1.24 1.02 1.51 1.32 1.08 1.60
(a) Adjusted for age, sex, current use of biguanides, sulfonylureas, insulin, or other antidiabetics (including DPP-4 inhibitors, glinides, GLP-1 analogs, and alpha
glucosidase inhibitors).
case-control study and found that the receipt of more than eight
TZD prescriptions was associated with an OR for fracture of 2.43
(1.49–3.95) versus no use of TZDs. The increased risk was found
for hip/femur, humerus, and wrist/forearm fractures and there
was a similar increase in women and men. From their prospec-
tive cohort study, Dormuth et al. (2009) concluded that treatment
with a TZD was associated with a 1.3-fold increased risk of periph-
eral fractures compared with treatment with a sulfonylureum [HR
1.28 (1.10–1.48)], regardless of sex. Habib et al. (2010) reported
in their cohort study that TZD users had a 1.4-fold increased
risk of fracture [HR 1.35 (1.05–1.71)]. Risks were increased for
women, but not for men, and for extremity fractures, but not
for fractures of the femur or vertebrae. Using a self-controlled
case series design, Douglas et al. (2009) found a within-person
rate ratio of 1.43 (1.25–1.62) for fracture comparing exposed with
unexposed periods among patients prescribed any TZD. Find-
ings were similar in men and women and the increased risk was
evident at a range of fracture sites, including hip, spine, arm,
foot, wrist, or hand. However, a recent study that evaluated the
performance of different study designs found that within-person
study designs had lower precision and greater susceptibility to bias
than cohort studies (Nicholas et al., 2012). Aubert et al. (2010)
showed in their cohort that TZD treatment was associated with
an increased risk of fracture in both men and women. The esti-
mated risk of fracture was nevertheless higher in women than in
men.
The different conclusions that are reached by observational
studies may thus be explained by the choice of different study
designs, but also by features of the registries that are used,
differences in prescribing habits between countries, and other dif-
ferences in patient characteristics or medication use. In our study,
we therefore explored heterogeneity between the three registries.
Several differences were observed. Fracture incidences were much
higher in Denmark than in the other two registries. This may be
due to higher incidence rates for fracture in Denmark (Kanis et al.,
2002), but also to more complete recording of all different fracture
types. From 1995 onward, inpatient and outpatient diagnoses are
captured in the Danish registries, while PHARMO only comprises
information on inpatient diagnoses. This probably explains the
low incidence rates for fractures of the extremities in PHARMO.
The proportion of patients who were prescribed a TZD was lower
in Denmark (4.2%) than in the GPRD (19.5%) and PHARMO
(12.2%). This may be caused by different marketing strategies for
TZDs in these countries, or by prescribing preferences of the physi-
cians. The use of AD co-medication also differed for TZD users
from the separate registries. For example, the use of insulin was
less common in users from the GPRD than from the other two
registries.
Despite all these considerations and differences between the
three countries, we actually found a fair amount of similarities
in outcomes when using the same study design. Firstly, fracture
risks for TZD users were only increased in women, not in men.
Secondly, there was a tendency for an increased risk of distal
fractures, although the number of fractures in PHARMO and Den-
mark was much lower than in GPRD (because the GPRD captured
more TZD users). Combining these three datasets in an individual
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Table 6 | Multi-country: risk of fracture in currentTZD users compared with other antidiabetic users, by number ofTZD prescriptions.
Multi-country
Fracture, n= Age-sex adj HR CI Fully adj HR (a) CI
No TZD 32,244 1 1
CURRENTTZD
Any fracture 1,644 1.25 1.18 1.31 1.27 1.21 1.34
Number of TZD prescriptions ever before
1–10 590 1.09 1.00 1.18 1.11 1.02 1.21
11–25 516 1.22 1.11 1.33 (c) 1.24 1.13 1.35 (c)
>25 538 1.56 1.43 1.70 (d) 1.59 1.46 1.74 (d)
Fracture of extremities (b) 981 1.45 1.35 1.55 1.49 1.39 1.59
Male 312 1.20 1.07 1.36 1.25 1.10 1.41
Female 669 1.60 1.47 1.73 1.64 1.51 1.78
Number of TZD prescriptions ever before
1–10 227 1.35 1.18 1.55 1.38 1.21 1.58
11–25 214 1.59 1.39 1.83 (c) 1.63 1.42 1.87 (c)
>25 228 1.99 1.74 2.29 (d) 2.06 1.79 2.36 (d)
(a) Adjusted for age, sex, current use of biguanides, sulfonylureas, insulin, or other antidiabetics (including DPP-4 inhibitors, glinides, GLP-1 analogs, and alpha glu-
cosidase inhibitors).
(b) Fracture of the tibia/fibula, ankle, foot, radius/ulna, humerus, wrist.
(c) Statistically significant difference between 11–25 and >25 prescriptions, based on Wald test.
(d) Statistically significant difference between 1–10 and >25 prescriptions, based on Wald test.
patient data meta-analysis increased the total number of fractures
and therefore enabled us to stratify risks to various relevant sub-
groups. These included different fracture types, sex, and duration
of use. It was even possible to stratify the risk of fracture in such
a way that all risk factors were combined: we estimated the risk
of fractures of the extremities in women, who were prolonged
users of TZDs. The estimate was significantly different from other
exposed groups.
The increased risk of fracture that we found may be caused
by different mechanisms. TZDs have been shown to increase the
expression of adipogenesis at the expense of osteoblastogene-
sis through activation of PPARγ (Benvenuti et al., 2007; Grey,
2008). However, this does not explain why fracture risks would
only be increased in women and not in men. A possible expla-
nation involves the finding that PPARγ ligands can stimulate the
differentiation of a number of cell types and not only those of
mesenchymal origin: Rubin et al. (2000) have demonstrated that
PPARγ ligands inhibit the expression of aromatase and hence
estrogen biosynthesis in adipose tissue. This may increase estrogen
deficiencies in menopausal women and thereby lead to increased
bone resorption and loss of trabeculae. Another recent study found
that TZD exposure in vitro may stimulate adipogenesis but does
not directly alter osteoblast differentiation, mineralization, or lin-
eage commitment from human bone marrow stromal cells (Beck
et al., 2012). Furthermore, TZDs may activate PPARγ in tissues
other than bone, such as the hypothalamus-pituitary-gonad axis
to indirectly regulate bone mass (Wei and Wan, 2011).
The specific risk of fractures of the extremities with the use
of TZDs is not fully understood. It has been demonstrated that
rosiglitazone administration in mice causes a loss of bone mass
in cortical bone, possibly through a decrease in bone formation
Database
Danish registries
GPRD
Pharmo
Total (95% CI)
Weight
14.8%
70.0%
15.2%
100.0%
1.03 [0.90, 1.18]
1.33 [1.25, 1.41]
1.22 [1.07, 1.39]
1.26 [1.20, 1.33]
Hazard Ratio [CI] Forest plot
0.5 0.7 1 1.5 2
Control MS
FIGURE 1 | Forest plot of age-sex adjusted Hazard Ratios for any
fracture.
expressed by decreased bone alkaline phosphatase (Broulík et al.,
2011). Another explanation may be a decrease in blood flow to the
extremities that causes an increase in the rate of bone loss (Vogt
et al., 1997).
Besides the use of TZDs, T2DM has also been associated with
adverse effects on the skeleton (Janghorbani et al., 2007; Vester-
gaard, 2007). Possible mechanisms include direct effects of the
high glucose levels on bone turnover (Williams et al., 1997),
increased urine calcium loss (McNair et al., 1979), and changes
in vitamin D metabolism (Bouillon, 1991). Complications of dia-
betes, such as neuropathy and angiopathy, may also contribute to
an increased risk of fracture.
There were several advantages to this multi-country study.
A major advantage of our study was the availability of indi-
vidual patient data from three different healthcare registries.
In total, we had information of more than 60,000 patients
who had used a TZD. There was detailed longitudinal informa-
tion on drug prescribing. But there are important limitations.
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HRs were adjusted for age, sex, and the use of AD medica-
tion other than TZDs, but not for other potential risk factors.
In our previous studies from PHARMO and the Danish reg-
istries, adjustments for other potential confounders did, however,
not substantially change the findings (Bazelier et al., 2012a,b).
The increased fracture risk that we found for prolonged users
of TZDs may be caused by the drug but also by the underlying
disease. By adjusting our analyses for the use of AD medica-
tion other than TZDs, we indirectly adjusted for the severity
of the underlying disease. Issues with latency of osteoporosis
may have led to protopathic bias in our studies; although not
registered in the databases, osteoporosis may already have been
noticed by a physician, which may have stopped him from pre-
scribing a TZD. The true associations between TZD use and the
risk of fracture may therefore be greater than reported in our
studies.
In conclusion, we found a 1.3-fold increased risk of frac-
ture for current TZD users versus users of other AD drugs,
using an individual patient data meta-analysis. The risk of frac-
ture with current TZD use was increased in women, but not
in men. TZD users had an increased risk for fractures of the
extremities, and risks further increased for prolonged users of
TZDs.
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